Skip to Content

FDA approves Zegerid for OTC treatment

From Datamonitor via COMTEX (December 3, 2009)

Merck & Co has reported that the FDA has approved Zegerid OTC for over-the-counter treatment of frequent heartburn.

Zegerid OTC will be marketed over-the-counter (OTC) by Schering-Plough HealthCare Products, the consumer healthcare division of Merck & Co.

According to Merck, Zegerid OTC is a proton pump inhibitor, an acid-reducing medication available for frequent heartburn. Zegerid OTC treats frequent heartburn by controlling and suppressing acid for a full 24 hours.

Zegerid OTC capsules will be available in their original prescription formula, and are expected to be available at drug stores, grocery stores, mass merchandisers and club stores in the first half of 2010.

Under an agreement with Santarus, a pharmaceutical company that developed and currently markets prescription Zegerid, Schering-Plough HealthCare Products is responsible for the development, manufacturing and commercialization of Zegerid OTC products for heartburn-related indications in the US and Canada. Santarus will continue to manufacture, promote and sell its Zegerid products in both 20mg and 40mg dosage strengths in the US.

Stan Barshay, executive vice president and president of Schering-Plough HealthCare Products, said: "Zegerid OTC is another demonstration of our commitment to bringing innovative treatments to consumers. For millions of Americans dealing with frequent heartburn, the availability of prescription-strength Zegerid OTC is important news and we're pleased to offer this unique, dual-ingredient, OTC product."


Posted: December 2009